{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:45:38Z","timestamp":1792107938524,"version":"4.4.0"},"reference-count":105,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,3,14]]},"abstract":"<jats:sec id=\"ab-jrv230005-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Heart failure with preserved ejection fraction (HFpEF), defined as HF with an EF of 50% or higher at diagnosis, affects approximately 3 million people in the US and up to 32 million people worldwide. Patients with HFpEF are hospitalized approximately 1.4 times per year and have an annual mortality rate of approximately 15%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv230005-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Risk factors for HFpEF include older age, hypertension, diabetes, dyslipidemia, and obesity. Approximately 65% of patients with HFpEF present with dyspnea and physical examination, chest radiographic, echocardiographic, or invasive hemodynamic evidence of HF with overt congestion (volume overload) at rest. Approximately 35% of patients with HFpEF present with \u201cunexplained\u201d dyspnea on exertion, meaning they do not have clear physical, radiographic, or echocardiographic signs of HF. These patients have elevated atrial pressures with exercise as measured with invasive hemodynamic stress testing or estimated with Doppler echocardiography stress testing. In unselected patients presenting with unexplained dyspnea, the H2FPEF score incorporating clinical (age, hypertension, obesity, atrial fibrillation status) and resting Doppler echocardiographic (estimated pulmonary artery systolic pressure or left atrial pressure) variables can assist with diagnosis (H2FPEF score range, 0-9; score &amp;amp;gt;5 indicates more than 95% probability of HFpEF). Specific causes of the clinical syndrome of HF with normal EF other than HFpEF should be identified and treated, such as valvular, infiltrative, or pericardial disease. First-line pharmacologic therapy consists of sodium-glucose cotransporter type 2 inhibitors, such as dapagliflozin or empagliflozin, which reduced HF hospitalization or cardiovascular death by approximately 20% compared with placebo in randomized clinical trials. Compared with usual care, exercise training and diet-induced weight loss produced clinically meaningful increases in functional capacity and quality of life in randomized clinical trials. Diuretics (typically loop diuretics, such as furosemide or torsemide) should be prescribed to patients with overt congestion to improve symptoms. Education in HF self-care (eg, adherence to medications and dietary restrictions, monitoring of symptoms and vital signs) can help avoid HF decompensation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv230005-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Approximately 3 million people in the US have HFpEF. First-line therapy consists of sodium-glucose cotransporter type 2 inhibitors, exercise, HF self-care, loop diuretics as needed to maintain euvolemia, and weight loss for patients with obesity and HFpEF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2023.2020","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T11:02:38Z","timestamp":1678791758000},"page":"827","source":"Crossref","is-referenced-by-count":640,"title":["Heart Failure With Preserved Ejection Fraction"],"prefix":"10.1001","volume":"329","author":[{"given":"Margaret M.","family":"Redfield","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Disease, Division of Circulatory Failure, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry A.","family":"Borlaug","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Division of Circulatory Failure, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"jrv230005r1","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics: 2022 update: a report from the American Heart Association.","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"issue":"18","key":"jrv230005r2","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"3","key":"jrv230005r3","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"17","key":"jrv230005r4","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology.","volume":"118","author":"Savarese","year":"2022","journal-title":"Cardiovasc Res"},{"issue":"19","key":"jrv230005r5","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1001\/archinte.168.19.2138","article-title":"Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis.","volume":"168","author":"Bahrami","year":"2008","journal-title":"Arch Intern Med"},{"issue":"14","key":"jrv230005r6","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.jacc.2013.01.022","article-title":"Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project.","volume":"61","author":"Huffman","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"jrv230005r7","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction.","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"jrv230005r8","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1161\/CIRCRESAHA.121.318172","article-title":"Epidemiology of heart failure: a contemporary perspective.","volume":"128","author":"Roger","year":"2021","journal-title":"Circ Res"},{"issue":"3","key":"jrv230005r9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction.","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv230005r10","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1056\/NEJMe068128","article-title":"Diastolic heart failure: a common and lethal condition by any name.","volume":"355","author":"Aurigemma","year":"2006","journal-title":"N Engl J Med"},{"issue":"18","key":"jrv230005r11","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","article-title":"Obesity and heart failure with preserved ejection fraction: new insights and pathophysiologic targets.","volume":"118","author":"Borlaug","year":"2022","journal-title":"Cardiovasc Res"},{"issue":"6","key":"jrv230005r12","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/jamainternmed.2015.0924","article-title":"A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010.","volume":"175","author":"Gerber","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"6","key":"jrv230005r13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.003116","article-title":"Predicting heart failure with preserved and reduced ejection fraction: the international collaboration on heart failure subtypes.","volume":"9","author":"Ho","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"8","key":"jrv230005r14","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jchf.2018.03.006","article-title":"Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction.","volume":"6","author":"Tsao","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"5","key":"jrv230005r15","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.jacc.2009.05.013","article-title":"Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction.","volume":"54","author":"Borlaug","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"jrv230005r16","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1161\/CIRCHEARTFAILURE.109.930701","article-title":"Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction.","volume":"3","author":"Borlaug","year":"2010","journal-title":"Circ Heart Fail"},{"issue":"11","key":"jrv230005r17","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jacc.2010.03.077","article-title":"Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction.","volume":"56","author":"Borlaug","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"jrv230005r18","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1016\/j.jacc.2014.03.034","article-title":"Implications of coronary artery disease in heart failure with preserved ejection fraction.","volume":"63","author":"Hwang","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"jrv230005r19","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/CIRCULATIONAHA.106.659763","article-title":"Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota.","volume":"115","author":"Lam","year":"2007","journal-title":"Circulation"},{"issue":"2","key":"jrv230005r20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1161\/CIRCHEARTFAILURE.114.001667","article-title":"Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction.","volume":"8","author":"Melenovsky","year":"2015","journal-title":"Circ Heart Fail"},{"issue":"6","key":"jrv230005r21","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1161\/CIRCULATIONAHA.114.009625","article-title":"Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction.","volume":"131","author":"Mohammed","year":"2015","journal-title":"Circulation"},{"issue":"11","key":"jrv230005r22","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.jacc.2021.07.014","article-title":"Exercise intolerance in older adults with heart failure with preserved ejection fraction: JACC state-of-the-art review.","volume":"78","author":"Pandey","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"37","key":"jrv230005r23","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1093\/eurheartj\/ehy531","article-title":"Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF.","volume":"39","author":"Shah","year":"2018","journal-title":"Eur Heart J"},{"issue":"10","key":"jrv230005r24","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1161\/CIRCULATIONAHA.113.001475","article-title":"Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study.","volume":"128","author":"Zakeri","year":"2013","journal-title":"Circulation"},{"issue":"19","key":"jrv230005r25","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1056\/NEJMoa032566","article-title":"Diastolic heart failure: abnormalities in active relaxation and passive stiffness of the left ventricle.","volume":"350","author":"Zile","year":"2004","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv230005r26","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1161\/CIR.0000000000001079","article-title":"Elucidating the clinical implications and pathophysiology of pulmonary hypertension in heart failure with preserved ejection fraction: a call to action: a science advisory from the American Heart Association.","volume":"146","author":"Brittain","year":"2022","journal-title":"Circulation"},{"issue":"17","key":"jrv230005r27","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1161\/CIRCULATIONAHA.117.031608","article-title":"Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction.","volume":"137","author":"Fayyaz","year":"2018","journal-title":"Circulation"},{"issue":"6","key":"jrv230005r28","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jchf.2016.03.001","article-title":"Impaired pulmonary diffusion in heart failure with preserved ejection fraction.","volume":"4","author":"Olson","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"36","key":"jrv230005r29","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1093\/eurheartj\/ehac184","article-title":"Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications.","volume":"43","author":"Omote","year":"2022","journal-title":"Eur Heart J"},{"issue":"48","key":"jrv230005r30","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1093\/eurheartj\/ehu193","article-title":"Right heart dysfunction in heart failure with preserved ejection fraction.","volume":"35","author":"Melenovsky","year":"2014","journal-title":"Eur Heart J"},{"issue":"25","key":"jrv230005r31","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1161\/CIRCULATIONAHA.113.008461","article-title":"Right ventricular function in heart failure with preserved ejection fraction: a community-based study.","volume":"130","author":"Mohammed","year":"2014","journal-title":"Circulation"},{"issue":"8","key":"jrv230005r32","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/eurheartj\/ehy809","article-title":"Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction.","volume":"40","author":"Obokata","year":"2019","journal-title":"Eur Heart J"},{"issue":"18","key":"jrv230005r33","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/j.jacc.2022.02.050","article-title":"Venous tone and stressed blood volume in heart failure: JACC review topic of the week.","volume":"79","author":"Fudim","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"jrv230005r34","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.ahj.2012.08.014","article-title":"Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction.","volume":"164","author":"Bishu","year":"2012","journal-title":"Am Heart J"},{"issue":"2","key":"jrv230005r35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.31083\/j.rcm2302069","article-title":"Interrelation between heart failure with preserved ejection fraction and renal impairment.","volume":"23","author":"Joslin","year":"2022","journal-title":"Rev Cardiovasc Med"},{"issue":"11","key":"jrv230005r36","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jacbts.2021.07.010","article-title":"Relationship of nonalcoholic fatty liver disease and heart failure with preserved ejection fraction.","volume":"6","author":"Salah","year":"2021","journal-title":"JACC Basic Transl Sci"},{"issue":"17","key":"jrv230005r37","doi-asserted-by":"publisher","first-page":"e484","DOI":"10.1161\/CIR.0000000000000596","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"issue":"5","key":"jrv230005r38","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/archinternmed.2010.427","article-title":"Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk.","volume":"171","author":"Sciarretta","year":"2011","journal-title":"Arch Intern Med"},{"issue":"1","key":"jrv230005r39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11906-019-0913-3","article-title":"Preventing heart failure by treating systolic hypertension: what does the SPRINT add?","volume":"21","author":"Upadhya","year":"2019","journal-title":"Curr Hypertens Rep"},{"issue":"10","key":"jrv230005r40","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1161\/CIRCRESAHA.121.318159","article-title":"From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited.","volume":"128","author":"Paulus","year":"2021","journal-title":"Circ Res"},{"issue":"12","key":"jrv230005r41","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1161\/CIRCULATIONAHA.119.041886","article-title":"Research priorities for heart failure with preserved ejection fraction: National Heart, Lung, and Blood Institute working group summary.","volume":"141","author":"Shah","year":"2020","journal-title":"Circulation"},{"issue":"11","key":"jrv230005r42","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/d41573-022-00158-3","article-title":"Accelerating therapeutic discoveries for heart failure: a new public-private partnership.","volume":"21","author":"Shah","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"jrv230005r43","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/ejhf.v25.2","article-title":"Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea.","volume":"387","author":"Omote","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"jrv230005r44","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction.","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"issue":"9","key":"jrv230005r45","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamacardio.2022.1916","article-title":"Diagnosis of heart failure with preserved ejection fraction among patients with unexplained dyspnea.","volume":"7","author":"Reddy","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"6","key":"jrv230005r46","doi-asserted-by":"publisher","DOI":"10.3399\/BJGPO.2021.0094","article-title":"Characteristics of patients with heart failure with preserved ejection fraction in primary care: a cross-sectional analysis.","volume":"5","author":"Forsyth","year":"2021","journal-title":"BJGP Open"},{"issue":"3","key":"jrv230005r47","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1002\/ehf2.v9.3","article-title":"Clinical characteristics and frailty status in heart failure with preserved vs. reduced ejection fraction.","volume":"9","author":"Hamada","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"6","key":"jrv230005r48","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1161\/CIRCHEARTFAILURE.112.968594","article-title":"Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study.","volume":"5","author":"Mohammed","year":"2012","journal-title":"Circ Heart Fail"},{"issue":"36","key":"jrv230005r49","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"5","key":"jrv230005r50","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1054\/jcaf.2002.128871","article-title":"Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria.","volume":"8","author":"Chen","year":"2002","journal-title":"J Card Fail"},{"issue":"8","key":"jrv230005r51","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.jacc.2003.11.040","article-title":"Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry.","volume":"43","author":"Klapholz","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"jrv230005r52","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jchf.2013.07.009","article-title":"Characterization of a novel symptom of advanced heart failure: bendopnea.","volume":"2","author":"Thibodeau","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"1","key":"jrv230005r53","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/ejhf.2017.19.issue-1","article-title":"Assessment of bendopnea impact on decompensated heart failure.","volume":"19","author":"Baeza-Trinidad","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"jrv230005r54","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jacc.2005.11.030","article-title":"B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure.","volume":"47","author":"Iwanaga","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"jrv230005r55","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/ejhf.v24.2","article-title":"Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity.","volume":"24","author":"Obokata","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"jrv230005r56","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.amjcard.2012.05.014","article-title":"Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction.","volume":"110","author":"Anjan","year":"2012","journal-title":"Am J Cardiol"},{"issue":"20","key":"jrv230005r57","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1093\/eurheartj\/ehab911","article-title":"Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality.","volume":"43","author":"Verbrugge","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"jrv230005r58","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jchf.2020.03.002","article-title":"Effects of sacubitril\/valsartan on N-terminal pro-B-type natriuretic peptide in heart failure with preserved ejection fraction.","volume":"8","author":"Cunningham","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"24","key":"jrv230005r59","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1016\/j.jacc.2021.04.055","article-title":"Natriuretic peptide deficiency in obese individuals: mechanistic insights from healthy organ donor cohort.","volume":"77","author":"Parcha","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"jrv230005r60","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction.","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"issue":"5","key":"jrv230005r61","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/j.chest.2020.05.552","article-title":"Performance and interpretation of invasive hemodynamic exercise testing.","volume":"158","author":"Jain","year":"2020","journal-title":"Chest"},{"issue":"9","key":"jrv230005r62","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.116.024822","article-title":"Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study.","volume":"135","author":"Obokata","year":"2017","journal-title":"Circulation"},{"issue":"12","key":"jrv230005r63","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/ehjci\/jew082","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.","volume":"17","author":"Nagueh","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"3","key":"jrv230005r64","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.mayocp.2022.07.025","article-title":"Risks of right heart catheterization and right ventricular biopsy: a 12-year.","volume":"98","author":"Hull","year":"2023","journal-title":"Single-Center Experience Mayo Clin Proc"},{"issue":"13","key":"jrv230005r65","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1001\/jama.2022.2037","article-title":"Cardiopulmonary exercise testing.","volume":"327","author":"de Boer","year":"2022","journal-title":"JAMA"},{"issue":"8","key":"jrv230005r66","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jchf.2018.03.003","article-title":"Hemodynamic correlates and diagnostic role of cardiopulmonary exercise testing in heart failure with preserved ejection fraction.","volume":"6","author":"Reddy","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"3","key":"jrv230005r67","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/joim.v289.3","article-title":"Systemic amyloidosis from A (AA) to T (ATTR): a review.","volume":"289","author":"Muchtar","year":"2021","journal-title":"J Intern Med"},{"issue":"11","key":"jrv230005r68","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction.","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"38","key":"jrv230005r69","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"issue":"10","key":"jrv230005r70","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1001\/jamacardio.2022.1781","article-title":"A simple score to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction.","volume":"7","author":"Davies","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"11","key":"jrv230005r71","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"jrv230005r72","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/ejhf.v21.11","article-title":"Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis.","volume":"21","author":"Jones","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"jrv230005r73","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"10354","key":"jrv230005r74","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"jrv230005r75","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"issue":"16","key":"jrv230005r76","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"jrv230005r77","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/eurheartj\/ehaa943","article-title":"Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.","volume":"42","author":"Abraham","year":"2021","journal-title":"Eur Heart J"},{"issue":"17","key":"jrv230005r78","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction.","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv230005r79","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure.","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"issue":"19","key":"jrv230005r80","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of sacubitril\/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial.","volume":"326","author":"Pieske","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"jrv230005r81","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial.","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"issue":"5","key":"jrv230005r82","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"issue":"8","key":"jrv230005r83","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"issue":"9386","key":"jrv230005r84","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial.","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"issue":"8","key":"jrv230005r85","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/ejhf.1149","article-title":"Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.","volume":"20","author":"Lund","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"jrv230005r86","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.34067\/KID.0001172021","article-title":"eGFR decline after SGLT2 inhibitor initiation: the tortoise and the hare reimagined.","volume":"2","author":"Meraz-Mu\u00f1oz","year":"2021","journal-title":"Kidney360"},{"issue":"1","key":"jrv230005r87","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/ehf2.v7.1","article-title":"Heart failure disease management: a systematic review of effectiveness in heart failure with preserved ejection fraction.","volume":"7","author":"Kalogirou","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"8","key":"jrv230005r88","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3390\/jcdd9080241","article-title":"Effects of exercise on heart failure with preserved ejection fraction: an updated review of literature.","volume":"9","author":"Crisci","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"issue":"4","key":"jrv230005r89","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10741-019-09774-5","article-title":"Effects of exercise training on cardiac function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials.","volume":"24","author":"Fukuta","year":"2019","journal-title":"Heart Fail Rev"},{"issue":"1","key":"jrv230005r90","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/jama.2015.17346","article-title":"Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial.","volume":"315","author":"Kitzman","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"jrv230005r91","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa2026141","article-title":"Physical rehabilitation for older patients hospitalized for heart failure.","volume":"385","author":"Kitzman","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"jrv230005r92","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jacc.2022.08.738","article-title":"Long-term changes in cardiac structure and function following bariatric surgery.","volume":"80","author":"Sorimachi","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"jrv230005r93","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1001\/jama.2022.23924","article-title":"Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial.","volume":"329","author":"Mentz","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"jrv230005r94","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons.","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"issue":"9","key":"jrv230005r95","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1002\/ejhf.v24.9","article-title":"Catheter ablation for patients with atrial fibrillation and heart failure: insights from the Swedish Heart Failure Registry.","volume":"24","author":"von Olshausen","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"jrv230005r96","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction.","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"jrv230005r97","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT: new insights into regional variation.","volume":"376","author":"de Denus","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv230005r98","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jchf.2018.10.017","article-title":"Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease.","volume":"7","author":"Beldhuis","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"23","key":"jrv230005r99","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction.","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"issue":"9766","key":"jrv230005r100","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S0140-6736(11)60101-3","article-title":"Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial.","volume":"377","author":"Abraham","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"jrv230005r101","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1161\/CIRCHEARTFAILURE.113.001229","article-title":"Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction.","volume":"7","author":"Adamson","year":"2014","journal-title":"Circ Heart Fail"},{"issue":"15","key":"jrv230005r102","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial.","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"15","key":"jrv230005r103","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1001\/jama.2020.16641","article-title":"Effect of praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction: the CAPACITY HFpEF randomized clinical trial.","volume":"324","author":"Udelson","year":"2020","journal-title":"JAMA"},{"key":"jrv230005r104","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.0675","article-title":"Rate-adaptive atrial pacing for heart failure with preserved ejection fraction: the RAPID-HF randomized clinical trial.","author":"Reddy","year":"2023","journal-title":"JAMA"},{"issue":"18","key":"jrv230005r105","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1001\/jama.2022.19590","article-title":"Treatment of hypertension: a review.","volume":"328","author":"Carey","year":"2022","journal-title":"JAMA"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2802310\/jama_redfield_2023_rv_230005_1678493507.36931.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T11:02:41Z","timestamp":1678791761000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2802310"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":105,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,3,14]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.2020","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,14]]}}}